Research and Studies
In controlled studies, PERIDAN™ Concentrate has…
Shown to be safe when administered intraperitoneally in an equine clinical model
- No septic peritonitis in a clean-contaminated model
- No affect on mechanical strength of anastomosis
- No affect on incision infection rate
Shown to be effective when administered intraperitoneally in an equine jejunal abrasion model
- 65% reduction in number of adhesions
- 76% decrease in severity of adhesions
- Shown to have favorable long-term outcome with regard to survival and colic
- Short-term survival 94%
- 84% of horses show no signs of colic
Shown to be safe and effective in a prospective study involving 29 horses and 4 foals undergoing abdominal surgery
- Short-term survival rate of 31/33 (94%)
- Long-term survival rate* of 29/31 (94%)
For more complete information regarding these and other studies, download the Technical reference guide
PERIDAN™ Concentrate is a product of Bioniche Animal Health
a division of Bioniche Life Sciences Inc.